This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

LX2931

Lexicon Pharmaceuticals, Inc.

Drug Names(s): LX3305

Description: LX2931 regulates lymphocytes by inhibiting S1P lyase, the enzyme that degrades S1P. The secreted messenger, S1P, interacts with S1P receptors such as S1P1 to regulate lymphocyte migration from lymphoid tissues (e.g., thymus and spleen).

In preclinical studies, LX2931 produced a consistent reduction in circulating lymphocyte counts in multiple species. In addition, LX2931 reduced joint inflammation and prevented arthritic destruction of joints in mouse models of arthritis.


LX2931 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug